Compare Enveric Biosciences Inc (ENVB) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Sony Group Corp — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Sony Group Corp trades at $24.07 (market cap $136.87B). The key difference: Sony Group Corp is far larger — about 20127.9× Enveric Biosciences Inc's market cap, and Sony Group Corp pays a 0.66% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Sony Group Corp for 96 Days on average.
| ENVB | SONY | |
|---|---|---|
Market Cap | $6.80M | $136.87B |
Volume | 64,867 | 5,364,503 |
Sector | Health | Technology |
52-Week High | $10.80 | $30.26 |
52-Week Low | $1.27 | $19.32 |
Typical Hold Time | 14 Days | 96 Days |
Enterprise Value | -$1.49M | $134.77B |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Sony trades at $23.52, down 1.38% on the day, with mixed technical signals showing a neutral overall trend. The company reported strong Q4 2025 and Q2 2026 earnings beats but missed Q1 2026 expectations. Revenue remains stable around $12.96T with solid gross margins of 31.82%, though net income margin turned negative at -1.75% for 2026. Analyst sentiment remains bullish with 11 buy ratings versus 5 holds.
Sony presents a compelling value case with reasonable valuation multiples (P/E 19.93, P/S 1.75) and strong cash flow generation. However, recent negative profitability metrics and the Q1 2026 earnings miss highlight execution risks. The company's diversified entertainment portfolio and AI positioning offer growth potential, but investors should monitor margin recovery and content performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
